Connect with us
European Gaming Congress 2024

Artificial Intelligence

Microcatheter Market – Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028.

Published

on

New York, Aug. 09, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Microcatheter Market – Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028.” – https://www.reportlinker.com/p06483191/?utm_source=GNW

Global Microcatheter Market is expected to grow with an impressive CAGR in the forecast period of 2024-2028. This can be attributed to factors such as the rising number of cases of cardiovascular diseases along with neurovascular issues prevalent across the globe.
Microcatheter is a device with a diameter of around 0.7-1.30 mm diameters which is utilized for guidewire support, accessing distal anatomy, delivering therapeutic inject contrast media, exchanges, and other procedures involved in complex endovascular procedures.
Other factors, such as the growing inclusion of microcatheters in minimally invasive diagnosis and therapeutic treatments along with rising research and development in the biotechnology and pharmaceutical industries, etc., are factors supporting the market growth and are expected to propel in the forecast period.
Rising Prevalence of Cardiovascular Diseases
The growing prevalence of the disease among the population is propelling the market demand for Microcatheter among the population.Rising cardiovascular disease prevalence is growing worldwide, causing a huge health concern among people around the world; for instance, according to the World Health Organization, Cardiovascular diseases (CVDs) are the leading causes of death globally.

In 2019, around 17.9 million people died from cardiovascular diseases, of which 85% were due to heart attacks and strokes. Also, over three-quarters of cardiovascular deaths occurred in low and middle-income countries. Cardiologists over the world are increasingly using microcatheters as a coronary interventional tool to treat complex coronary interventions like bifurcation lesions, ostial location, tortuous anatomy, angled takeoffs, coronary calcification, and chronic total occlusion (CTO) percutaneous coronary intervention (PCI). The increased usage of microcatheters in the diagnosis and treatment procedures is thus bolstering the demand for the microcatheters market and is anticipated to increase with increased CVDs in the forecast period.
Growing Demand in Minimally Invasive Surgeries
Growing demand for Microcatheter is required in multiple fields of life sciences due to the wide range of diagnostic and therapeutic applications.Microcatheters are tiny, hollow tubes used in a variety of interventional procedures put into blood vessels.

They are utilized in different diagnostic and therapeutic procedures and are designed to deliver various interventional devices into the blood arteries.Common usage of microcatheter is in urinary microcatheters, arterial microcatheters, peripheral microcatheters, and neurovascular microcatheters.

Microcatheters have the capability to reach even the most complex network of veins; thus, they can be widely utilized and is in high demand for minimally invasive therapies and treatment, driving the market growth and is anticipated to bolster the market demand in the forecast period.
Technological Advancement
Several technological advancements have been introduced in microcatheters to improve deliverability and reduce deformations and mishandling.Technological advancement, such as, the addition of a feature to developed microcatheters which offer additional options for guidewire support during CTO Chronic total occlusion) and PCI(Percutaneous Coronary Interventions).

Advertisement
Stake.com

Also, meanwhile using microsensing devices, the bending characteristics of the microcatheter can be controlled for an effective transit through the convoluted vasculature.To create an outstanding control mechanism for accurate layer bending, actuators such as pressure sensors, CMOS circuitry, and polymer conducting layers are used.

Also, to improve result efficacy and precise control approaches, deep learning and artificial intelligence (AI) techniques are some viable tools.
Recent Developments
• Boston Scientific Corporation got FDA approval in April 2022 for its EMBOLD Fibered Detachable Coil, which is intended to impede or slow blood flow in the peripheral vasculature. The option to use many catheters offers flexibility in choosing a catheter and helps reduce the possibility of device exchanges, which increases operation productivity and allows for better patient outcomes.
• In 2021, Terumo medical corporation launched its recent microcatheter named PG Pro Peripheral Microcatheter.
Market Segmentation
Global Microcatheter Market is segmented based on type, design, application, end-user, and region.Based on the type, the market is segmented into delivery, diagnostic, aspiration, and steerable.

Based on the design, the market is segmented into Single and Dual.Based on application, the market is further fragmented into cardiovascular, neurovascular, peripheral vascular, and oncology.

Depending on the end user, the market is segmented into hospital & ambulatory surgical centers, vascular, and oncology. Based on the region, the market is further segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa (MEA).
Market Players
Boston Scientific Corporation, Stryker Corporation, Teleflex Incorporated, Cook Group, Becton Dickinson and Company, Asahi Intecc Co. ltd., Terumo Medical Corporation, Medtronic Plc., Johnson & Johnson, Teleflex Incorporated., etc., are some of the major players operating in the global Microcatheter Market.

Report Scope:

Advertisement
Stake.com

In this report, Global Microcatheter Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Microcatheter Market, By Type:
o Delivery
o Diagnostic
o Aspiration
o Steerable
• Microcatheter Market, By Design:
o Single
o Dual
• Microcatheter Market, By Application:
o Cardiovascular
o Neurovascular
o Peripheral Vascular
o Oncology
• Microcatheter Market, By End User:
o Hospital & Ambulatory Surgical Centers
o Vascular
o Oncology
• Microcatheter Market, By Region:
o North America
United States
Canada
Mexico
o Europe
Germany
France
United Kingdom
Italy
Spain
o Asia-Pacific
China
Japan
India
South Korea
Australia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
o South America
Brazil
Argentina
Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Microcatheter Market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Advertisement
Stake.com

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06483191/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


Advertisement
Stake.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Transforming Healthcare with AI: Yidu Tech’s Gong Rujing at Summer Davos

Published

on

transforming-healthcare-with-ai:-yidu-tech’s-gong-rujing-at-summer-davos

DALIAN, China, July 1, 2024 /PRNewswire/ — “AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry.” At the 15th Annual Meeting of the New Champions, also known as Summer Davos, Ms. Gong Rujing (Yingying), Chairwoman and Founder of Yidu Tech, was invited as a distinguished representative of the healthcare technology sector. She shared her unique insights into the future of AI in healthcare during the thematic dialogue on “Healthcare Analytics, Not Moving Fast Enough.”

This year marks the 10th anniversary of Yidu Tech and Ms. Gong Rujing’s decade-long dedication to the healthcare industry. From the inception of her entrepreneurial journey 10 years ago, she has been driven by the mission to leverage the power of technology to deliver precise healthcare to every individual.
Ms. Gong described the past decade as a journey filled with miracles and achievements. During this period, Yidu Tech has progressively established close collaborations with key stakeholders in the healthcare industry, including government agencies, hospitals, pharmaceutical companies, insurance firms, experts, and clinicians. As of March 31, 2024, Yidu Tech’s “AI Medical Brain” YiduCore has been authorized to process and analyze over 5 billion medical records, covering more than 2,500 hospitals.
In AI-powered clinical research, Yidu Tech has supported researchers and clinicians in producing over 240 high-level papers, accelerating the application of research outcomes. Additionally, Yidu Tech provides clinical trial services to globally renowned pharmaceutical companies, helping them optimize trial processes, reduce costs, and bring new drugs to market more swiftly, ultimately benefiting patients. In healthcare management, Yidu Tech’s AI technology plays a crucial role by analyzing vast amounts of medical data to provide comprehensive decision support to healthcare administrators, helping them optimize resource allocation and improve service efficiency.
“We are now entering a new era of AI technology.” The development of large language model technologies has opened up new possibilities across various industries. Yidu Tech has independently developed a large language model specific to the medical field and is advancing its application across the entire healthcare industry chain. The goal is to promote further progress and innovation through new AI technologies. However, Ms. Gong also emphasized that the healthcare industry is professional, complex, and sensitive, and the application of new technologies must address challenges such as data security, privacy protection, and ethics.
“Data security and privacy protection are fundamental to the development of AI technology and medical big data technology. We must ensure that all stakeholders are satisfied with compliance, security, accessibility, and privacy protection.”
“AI technology still has a long way to go.” She called on policymakers, healthcare institutions, and technology companies to work together to realize the immense potential of healthcare data. Ms. Gong highlighted that building trust is key, and enhancing data operability is essential to fully unleash the power of data. “It’s not just about better data quality; it’s about a better future for health.”

View original content:https://www.prnewswire.co.uk/news-releases/transforming-healthcare-with-ai-yidu-techs-gong-rujing-at-summer-davos-302186561.html

Continue Reading

Artificial Intelligence

Yidu Tech’s FY2024 results: existing business achieves first full-year profit on adjusted EBITDA

Published

on

yidu-tech’s-fy2024-results:-existing-business-achieves-first-full-year-profit-on-adjusted-ebitda

HONG KONG, July 1, 2024 /PRNewswire/ — On June 27, 2024, Yidu Tech Inc. (the ”Company” or ”Yidu Tech”) (2158.HK), a leader in China’s AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million. Gross profit margin in FY2024 increased to 42.1% from 34.1% in FY2023, representing an increase of 8 percentage points, hitting a record high. Adjusted net loss narrowed from RMB 448.7 million in FY2023 to RMB158.1 million, down 64.8% year-on-year. The management of Yidu Tech said at the annual results conference the next day that excluding strategic investments in proprietary large language model, non-cash items, and non-operating items, the adjusted EBITDA for our current business has achieved profit, moving from a RMB 327 million loss to a profit of RMB 31.1 million for the first time this fiscal year.

Management added that as of market close on June 27, the Company’s P/B ratio has decreased to 1.06. Not including the valuation of its domestic and international businesses, its market value is still lower than its fund reserves on hand. As such, management believes that the Company’s share price is still severely undervalued. Notably, renowned sovereign fund BIA has continually increased its shareholding of Yidu Tech by 21.50% over the past two months. The management is confident in the Company’s long-term growth potential and hopes to continually create innovative technologies and increase returns to its shareholders.
In FY2024, Yidu Tech focused on its core business, improving internal operating efficiency and earning quality. Among its earnings, revenue from its big data platform and solutions segment reached RMB 313.6 million, an increase of 41.4% year-on-year. Revenue from its life science solutions segment reached RMB 324.0 million, up 28.1% year-on-year and the gross margin increased by 14.6 percentage points to a historical high of 32.1%. Revenue from its health management platform and solutions segment reached RMB 169.5 million, and the gross profit margin of this segment was 58.1%, representing a year-on-year increase of 17.4 percentage points.
During the reporting period, the Company has continued the development and training of large language model in the medical vertical field based on 500 billion fine-trained Tokens, with model training for 6B, 13B, and 70B parameters completed.

View original content:https://www.prnewswire.co.uk/news-releases/yidu-techs-fy2024-results-existing-business-achieves-first-full-year-profit-on-adjusted-ebitda-302185986.html

Continue Reading

Artificial Intelligence

Lucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024

Published

on

lucinity’s-ai-innovation-recognized-at-microsoft’s-prestigious-global-partner-awards-2024

REYKJAVIK, Iceland, June 28, 2024 /PRNewswire/ — Lucinity has been recognized as a finalist in the AI Innovation category at the prestigious Microsoft Global Partner Awards 2024, recognizing its breakthrough AI solution and contribution to financial security through its collaboration with Microsoft. 

Lucinity beat more than 4,700 companies to be named a finalist at the annual Microsoft Global Partner Awards, which highlights Lucinity’s achievements as a Microsoft partner in optimizing business processes, improving customer experiences, and opening new pathways for digital transformation.
This achievement comes in addition to winning two prestigious awards at Microsoft Partner Awards 2024 last month, including Partner of the Year – Iceland, and the Sustainability and Social Impact award.
The accolade recognizes Lucinity’s significant advancements in AI for financial crime operations, particularly through their AI-powered copilot, Luci. This innovative solution utilizes Microsoft Azure OpenAI technology to integrate advanced generative AI into financial crime investigations and regulatory compliance, optimizing processes and saving significant time and resources for financial institutions.
The Lucinity platform streamlines compliance, provides instant insights, and reduces typical investigation times from three hours to just 30 minutes. The technology can also save financial institutions an estimated $100 million in productivity savings, as well as savings in training and recruitment.
Microsoft comments on Lucinity’s award recognition, saying “Financial crime profoundly impacts our global community, with far-reaching economic, security, and social implications. It can harm a country’s reputation and increase exposure to criminal activities, emphasizing the critical need for robust anti-money laundering initiatives and persistent vigilance. Lucinity, with their innovative AI solutions, has really tried to combat this huge global challenge. They use ‘Human AI’ to enhance financial crime prevention, combining AI with human expertise for efficient, user-friendly solutions. Additionally, Lucinity has developed a tool called Luci, an AI-powered copilot that helps transform financial crime prevention from a process that took hours to one that takes minutes.”
“Being recognized as a finalist at the Microsoft Global Partner Awards is  validation of our impactful collaboration with Microsoft in financial crime operations. Our partnership has been pivotal for our innovations, enabling us to use Azure OpenAI to bring tools like Luci to life and deliver impactful results for our clients,” says Guðmundur Kristjánsson, Founder & CEO of Lucinity.
Contact:Name: Celina PabloEmail: [email protected]: +354 792 4321
Logo: https://mma.prnewswire.com/media/2208676/4669079/Lucinity_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lucinitys-ai-innovation-recognized-at-microsofts-prestigious-global-partner-awards-2024-302186091.html

Continue Reading

Trending